Mirati’s Adagrasib Challenger Fails To Differentiate Itself From Amgen’s Lumakras

 
• By Ayisha Sharma

While adagrasib showed decent efficacy in its pivotal study in NSCLC, some analysts said its inability to outperform Amgen’s Lumakras and its safety profile leave little room for differentiation.  

Adagrasib Must Stand Out From The Crowd If It Wants Market Success • Source: Shutterstock

More from Clinical Trials

More from R&D